|Lamis AA KAddam, PhD|
|Dalya MM Abdelmaged, MBBS|
1 Sudan site
3 to 18 Years
Phase 2/Phase 3
– Homozygous for Sickle Cell Disease (SS) as documented by Haemoglobin electrophoresis.
Subjects whom medications and dosages had been stable for 2 weeks before study entry.
Subjects who have not received blood transfusion or had acute episode related to sickle
cell disease in the last two weeks before the start of intervention.
– Patients with history of Gum Arabic allergy. Patients who have ischemic heart disease,
liver dysfunction or hepatitis. Pregnant female patients who plan to conceive in the
next 4 months and fertile female patients who are not using an effective contraception
Patients who are currently using Gum Arabic. Patients who are on steroids or chemotherapy.